Zoledronic acid - Axsome Therapeutics

Drug Profile

Zoledronic acid - Axsome Therapeutics

Alternative Names: AXS 02; Disodium (1-Hydroxy-2-(1H-Imidazol-1-yl)-1- Phosphonoethyl)Phosphonic Acid - Axsome Therapeutics; Disodium zoledronate tetrahydrate - Axsome Therapeutics; Oral zoledronate

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ANTECIP BIOVENTURES
  • Developer Axsome Therapeutics
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain
  • Phase II Back pain

Most Recent Events

  • 27 Mar 2018 Axsome Therapeutics plans a phase III trial for Back pain (chronic low back pain with modic changes)
  • 09 Jan 2018 Axsome Therapeutics terminates the phase III CREATE-1 trial in Pain in USA, Australia, Canada and United Kingdom (NCT02504008)
  • 01 Feb 2017 Axsome receives IND clearance from the US FDA for its phase III trial in Back pain (10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top